Advances in pharma and biotech are critical for the progression of modern medicine, but at what cost to the environment? In this exclusive video interview with Technology Networks, My Green Lab’s CEO James Connelly discussed why our recently released 2023 Carbon Impact of Biotech and Pharma report is so important, its key findings, and steps that laboratories can take to reduce their carbon emissions. Watch the video here: https://lnkd.in/g7m-UG-A Download the 2023 report here: https://lnkd.in/eC5cUkun
My Green Lab’s Post
More Relevant Posts
-
If you missed the 2023 report during the craze of the holidays, check out this interview and take a deeper dive with the report from our friends at My Green Lab. A great resolution for 2024 is reducing the Scope 3 emissions associated with your lab. #SustainableInnovation #Scope3Emissions #Decarbonize
Advances in pharma and biotech are critical for the progression of modern medicine, but at what cost to the environment? In this exclusive video interview with Technology Networks, My Green Lab’s CEO James Connelly discussed why our recently released 2023 Carbon Impact of Biotech and Pharma report is so important, its key findings, and steps that laboratories can take to reduce their carbon emissions. Watch the video here: https://lnkd.in/g7m-UG-A Download the 2023 report here: https://lnkd.in/eC5cUkun
The Environmental Impact of Biotech and Pharma With My Green Lab
technologynetworks.com
-
Reputation/Brand + ESG/Sustainability + Executive Leadership + Geopolitics/Policy + Communications/Crisis
Learn how #Biomimetics applies to your future business strategy.
Our company is proud to announce that we are a founding sponsor of Biomimetics24 taking place in Minneapolis at the University of Minnesota on October 8, 2024. Click below to learn more and register. https://lnkd.in/ghMy2Fpk #natureinspired #TheHumanverse #SDGs #ESG #biomimicry
Biomimetics24 | Industry Strategy Symposium
biomimetics24.org
-
𝗜𝗻𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗶𝗻𝗴 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀: 𝗥𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗮𝗿𝗯𝗼𝗻 𝗳𝗼𝗼𝘁𝗽𝗿𝗶𝗻𝘁 𝗼𝗳 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 At the 7th International Clinical Trials Methodology Conference 2024, sustainability was in the spotlight as researchers discussed how to reduce the carbon impact of clinical trials. From transportation logistics to energy-heavy lab processes, every aspect of clinical research can contribute to emissions. 1️⃣ Carbon culprits: The transport of samples and participants is one of the biggest carbon contributors in clinical trials 2️⃣ Industry action: Pharma giants like AstraZeneca and Johnson & Johnson are taking steps to embed sustainability in research processes 3️⃣ Innovative solutions: Decentralized trials and AI-powered logistics are emerging as ways to reduce emissions in medical research 💬 Could sustainability become a core principle in the future of clinical trials? 📖 Read the full analysis by illuminem voice Michelle Arellano-Meza, currently leading Future Energy Leaders programme at the World Energy Council here: https://lnkd.in/ecNpmy9X #sustainability #clinicaltrials #decarbonization #medicalresearch #carbonfootprint
-
-
Every year, the Novo Nordisk Foundation reports on progress in research advancements, inventions, and patient treatment. The impact report serves as a testament to the Foundation's commitment to making a significant scienfic and broader societal impact on public health, sustainable development and the condition of the planet. One of the analyses in the report investigates the research the funded and how it underpins development of technology. For the first time, we see Industrial Biotechnology as one of the most common areas of research and Climate Change Mitigation Technology as one of the most common patent technology classifications highlighting - an early indication of the Foundation's shift in strategy to also focus on the sustainability of the planet. Read the report here: https://lnkd.in/dbRdkU5K The team behind the report is the Impact Area: Thomas Alslev Christensen, Henrik Barslund Fosse, Gert V. Balling, Rikke Christensen, Joan Bentzen, Rasmus Lund Jensen, Daryl Paul, Sandra Schluttenhofer, Emil Søndergaard Hansen, Anders Agerbæk Kjøller Nielsen, Kristian Raudal, Jens Christian Petersen.
-
-
Circulair economy will be key in the future.Join this seminar to get your excisting and new bioprocessing in tip top shape for now and the future.
I have recently been asked, "How do you use your voice?" 🗣 And in all fairness, as an #introvert and #neurodivergent the answer is "scarcely and quietly". I use my voice mostly in more private settings, internally with my team, or in 1:1 conversations, where I feel safe and heard. But on rare occasions, you can hear me loud and clear in public. That is when I feel strongly about a topic that is being discussed, and I believe that my voice can meaningfully contribute to taking action, teaching, or empowering others. I want to drive the change, not just fill the air with noise. And now, there comes a rare moment, when I feel again bold enough to speak up. In the upcoming webinar for the bioeconomy organised by EV Biotech in collaboration with, Synonym, Arxada, and Bio Base Europe Pilot Plant, together with other panellists we will focus on: - how #modelling can speed up the #commercialization of #bioproducts, - what are the different types of purpose-driven models that assist in scaling up #industrial #bioprocesses, - and also, on current models' shortcomings. Why do I care? I strongly believe that in order to make the #circular #economy a reality now, not in 20 years, we need to use the most up-to-date tools, including digital ones, to de-risk, and speed up the introduction of #bioprocesses on a global scale. 📅 Date: September 25, 2024 🕒 Time: 4pm to 5:30pm CET 📍 Sign up for the webinar here: https://lnkd.in/eCqmmf6j The webinar is part of the 12th edition of the #EuropeanBiotechWeek, a week-long (from 24 September to 1 October 2024) series of events aiming at making #biotech accessible to everyone and showing how it surrounds and supports us in everyday life (more at www.biotechweek.org). EuropaBio - the European Association for Bioindustries
-
Today is a new day that #science and #business fabric gather to search for a new future! This Thursday, several companies will gather in the Forum Braga Congress Room for different rounds of Biotech Flash Talks and Speed Meetings. This initiative of #EXPOBIOTEC – Braga #Biotechnology Week 2024 aims to promote the interconnection between science and companies and, at the same time, seek new models of collaboration and innovation. The information is all here: https://lnkd.in/dDAcRiT8
-
-
The golden era of bioenhancements has begun, yet the question arises: are we steering in the right direction? Pioneering the longevity era will require educating, delivering, and developing new bioenhancement tools, building an unparalleled biotech ecosystem. Read my latest on X. https://lnkd.in/dpsGcYq7
-
-
Berlin on April 16, 2024 at the Biotechnology conference, our Vice President Kirsten Tief-Kuery joined a panel discussion on 'How Europe's Biotechnology sector remains its competitiveness'. 🌱 It's clear that the region's unique ecosystem presents a significant opportunity for progress and growth. However, to fully leverage this potential, we need an innovation-friendly regulatory environment that fosters investment in R&D and promotes market access. Harmonized frameworks at both national and EU levels are crucial to remove regulatory barriers, accelerate market access, and enhance global competitiveness. Improving access to feedstock, recognizing sustainability efforts, supporting infrastructure scale-up, and enhancing skills accessibility are also key areas for advancement. Together, we can propel the EU region to new heights of strength and competitiveness in biotechnology. #Biotech #Innovation #EURegulation #Sustainability #GrowthOpportunities 🚀🔬#DBT2024 Thank you @Claire Skentelbery for your fantastic moderation and all panelists for the valuable insights : Martin Krauss from FGK, Klaus Pellengahr from Corden BioChem GmbH, Anna Eichhorn from Humatrix AG Thermo Fisher Scientific ,Kirsten Tief-Kuery, Vicky Voulgaraki,BIO Deutschland e. V.; Viola Bronsema; Oliver Schacht; Franziska Freund Urmi Prasad Richardson Jo Van den Broeck Musa SaniRoland Geyer Christian Fiedler Peter Mark Dr. Philipp Kuegler Anil Kane, Ph.D., MBA
-
-
📢 Yesterday, the European Commission published the Communication “Building the Future with Nature: Biotechnologies and Biomanufacturing in the EU”, proposing a series of targeted actions to boost #biotechnology and #biomanufacturing in the EU, as important enablers for the #competitiveness of the European industry 💪 and the #bioeconomy at large. 🍃 💡 The actions include: 1️⃣ Simplified regulatory framework and faster access to the market 2️⃣ Better support for scale-up and ease of navigating regulations 3️⃣ Use of AI and generative AI in biotechnology 4️⃣ Foster more private investments 5️⃣ More public investments to encourage private investments in the sector 6️⃣ Enable fair comparison with fossil-based products 7️⃣ Bigger market for biotechnology and biomanufacturing 8️⃣ Review the 2012 EU Bioeconomy Strategy by the end of 2025, reinforcing its industrial dimension and its links to biotechnology and biomanufacturing to contribute to a stronger EU economy. 👉 Read the Communication at https://buff.ly/3VrI9VV Circular Bio-based Europe Joint Undertaking (CBE JU) Bio-based Industries Consortium (BIC) EuropaBio - the European Association for Bioindustries
-
-
In the biotech world, groundbreaking science isn't enough. It’s about strategy, market positioning, and a strong value proposition. Join us in our exclusive Better Biotech Growth webinar series, where our experts, Dr. Simone Seiter and Kevin Baruzzi, uncover what it really takes to ensure your biotech product not only enters the market but thrives. Register now to gain actionable insights and practical strategies from our experts: skp.link/b6h4 #BetterBiotechGrowth #Biotech #CommercialExcellence #SimonKucher #BiotechGrowth
-
